Analyst: Bavarian Nordic continues hot streak

A run of very good news for the Danish vaccine maker, including winning the European monkeypox authorization as the infection is declared a global threat, is evident on a skyrocketing stock price.


On Monday, the EU Commission authorized Bavarian Nordic to broaden its vaccine label for smallpox vaccine Imvanex, adding monkeypox. This followed hot on the heels of the European Medicines Agency’s approval recommendation on Friday.

While that took place, the World Health Organization (WHO) decided to categorize the monkeypox outbreak as a global health emergency, the authority’s highest level of alert.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs